[go: up one dir, main page]

MA35271B1 - Antagonistes de trpm8 et leur utilisation dans des traitements - Google Patents

Antagonistes de trpm8 et leur utilisation dans des traitements

Info

Publication number
MA35271B1
MA35271B1 MA36692A MA36692A MA35271B1 MA 35271 B1 MA35271 B1 MA 35271B1 MA 36692 A MA36692 A MA 36692A MA 36692 A MA36692 A MA 36692A MA 35271 B1 MA35271 B1 MA 35271B1
Authority
MA
Morocco
Prior art keywords
disorders
trpm8
compounds
antagonists
treatments
Prior art date
Application number
MA36692A
Other languages
English (en)
Inventor
Kaustav Biswas
James Brown
Jian J Chen
Vijay Keshav Gore
Scott Harried
Daniel B Horne
Matthew R Kaller
Qingyian Liu
Vu Van Ma
Holger Monenschein
Thomas T Nguyen
Chester Chenguang Yuan
Wenge Zhong
Jean David J St Jr
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA35271B1 publication Critical patent/MA35271B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

L'invention concerne des composés de formule (i) servant comme antagonistes de trpm8. De tels composés servent à traiter une pluralité de troubles et maladies à médiation par trpm8 et peuvent être utilisés pour préparer des médicaments et des compositions pharmaceutiques servant à traiter de tels troubles et maladies. De tels troubles peuvent être, de façon non exhaustive, les migraines et les douleurs neuropathiques. Les composés de formule (i) ont une structure dont les définitions des variables sont fournies ici.
MA36692A 2011-06-24 2014-01-20 Antagonistes de trpm8 et leur utilisation dans des traitements MA35271B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500843P 2011-06-24 2011-06-24
PCT/US2012/043566 WO2012177893A2 (fr) 2011-06-24 2012-06-21 Antagonistes de trpm8 et leur utilisation dans des traitements

Publications (1)

Publication Number Publication Date
MA35271B1 true MA35271B1 (fr) 2014-07-03

Family

ID=46384521

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36692A MA35271B1 (fr) 2011-06-24 2014-01-20 Antagonistes de trpm8 et leur utilisation dans des traitements

Country Status (23)

Country Link
US (3) US8710043B2 (fr)
EP (1) EP2723717A2 (fr)
JP (1) JP2014527511A (fr)
KR (1) KR20140045507A (fr)
CN (1) CN103906733A (fr)
AP (1) AP2013007331A0 (fr)
AR (1) AR086750A1 (fr)
AU (1) AU2012272895B2 (fr)
BR (1) BR112013033316A2 (fr)
CA (1) CA2839699A1 (fr)
CL (1) CL2013003715A1 (fr)
CO (1) CO6852073A2 (fr)
CR (1) CR20140037A (fr)
EA (1) EA201490152A1 (fr)
MA (1) MA35271B1 (fr)
MX (1) MX2013015274A (fr)
MY (1) MY157429A (fr)
PE (1) PE20140868A1 (fr)
PH (1) PH12013502611A1 (fr)
TN (1) TN2013000529A1 (fr)
TW (2) TW201429948A (fr)
UY (1) UY34160A (fr)
WO (1) WO2012177893A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CA2962922C (fr) * 2014-09-29 2021-10-26 The Scripps Research Institute Modulateurs du recepteur de la sphingosine -1-phosphate pour le traitement de troubles cardio-pulmonaires
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
ES2957232T3 (es) * 2016-06-13 2024-01-15 Mitsubishi Tanabe Pharma Corp Composiciones para el tratamiento o la prevención de síntomas vasomotores
JP2020524717A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
WO2018234808A1 (fr) 2017-06-22 2018-12-27 Curadev Pharma Limited Modulateurs à petites molécules de sting humain
WO2019124366A1 (fr) 2017-12-19 2019-06-27 Mitsubishi Tanabe Pharma Corporation Compositions et méthodes de traitement ou de prévention de symptômes vasomoteurs
WO2019180627A1 (fr) * 2018-03-21 2019-09-26 Piramal Enterprises Limited Synthèse asymétrique améliorée d'alpha-(diarylméthyl)alkylamines
WO2019202522A1 (fr) * 2018-04-18 2019-10-24 Piramal Enterprises Limited Synthèse asymétrique améliorée d'amines chirales alpha-ramifiées
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
KR20230026404A (ko) * 2020-06-17 2023-02-24 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
WO2021257490A1 (fr) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxoimidazolidine-4-carboxamides utilisés en tant qu'inhibiteurs de nav1.8
CN115697327A (zh) * 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
CA3221549A1 (fr) * 2021-06-08 2022-12-15 Liqiang Fu Composes d'isoindolinone et leurs utilisations
CN115108980B (zh) * 2022-06-22 2023-06-16 济南大学 一种2-甲基喹啉类化合物的4号位酰基化衍生物的制备方法
WO2025113520A1 (fr) * 2023-11-28 2025-06-05 成都地奥制药集团有限公司 Composé amide et son utilisation
CN119118901B (zh) * 2024-09-09 2025-09-30 中国人民解放军北部战区总医院 一种氧吲哚类衍生物及其制备方法与在trpa1抑制剂方向的应用

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483250A (en) 1949-09-27 Tt a it tt
DE2417763A1 (de) 1974-04-11 1975-10-30 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2428673A1 (de) 1974-06-14 1976-01-02 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5081131A (en) 1986-01-13 1992-01-14 American Cyanamid Company Omega-((hetero)alkyl)benz(cd)-indol-2-amines
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
ZA913730B (en) 1990-05-30 1992-02-26 Ici Plc Anti-tumor compounds
US5380721A (en) 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
WO1992012973A1 (fr) 1991-01-23 1992-08-06 Nippon Kayaku Kabushiki Kaisha Derive de chromane
ES2036926B1 (es) 1991-08-08 1994-01-16 Uriach & Cia Sa J "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE4138819A1 (de) 1991-11-26 1993-05-27 Basf Ag Hydroxypyridoncarbonsaeureamide, deren herstellung und verwendung
GB9127041D0 (en) 1991-12-20 1992-02-19 Fujisawa Pharmaceutical Co New use
FR2692895A1 (fr) 1992-06-26 1993-12-31 Adir Nouveaux 1-oxo 2,4,5,6-tétrahydro 2,3,7-triazaphénalènes leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
EP0653434A1 (fr) 1993-11-12 1995-05-17 Tanabe Seiyaku Co., Ltd. Dérivés de glucosamine, leur procédé de préparation et leur intermédiaires
CA2207618A1 (fr) 1994-12-23 1996-07-04 Helmut Pieper Derives de piperazine, medicaments contenant ces composes, leur utilisation et leur procede de preparation
US5916906A (en) 1995-03-14 1999-06-29 Shaskan; Edward G. Compositions comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin B6
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
IN186549B (fr) 1995-04-19 2001-09-29 Kumiai Chemical Co Ltd
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
DE19523087A1 (de) 1995-06-26 1997-01-02 Bayer Ag 1,3-Oxa(thia)zin-Derivate
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
EP0858457A1 (fr) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants
GB9525828D0 (en) 1995-12-18 1996-02-21 Bayer Ag Use of hetarylacetic acid derivatives
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US6075029A (en) 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
JP4432261B2 (ja) 1998-01-21 2010-03-17 萬有製薬株式会社 複素芳香環縮合シクロペンテノピリジン誘導体
EP1082095A1 (fr) 1998-06-03 2001-03-14 GPI NIL Holdings, Inc. Compositions pour la croissance des cheveux a base de n-oxydes de ketones, de thioesters, d'amides ou d'esters heterocycliques, et utilisation de ces compositions
US5910595A (en) 1998-06-26 1999-06-08 Salsbury Chemicals, Inc. Process for preparing oximidazoles
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
WO2000035889A1 (fr) 1998-12-11 2000-06-22 Sankyo Company, Limited Benzylamines substituees
WO2000039102A1 (fr) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company INHIBITEURS DE LA THROMBINE OU DU FACTEUR Xa
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
TR200002099A2 (tr) 1999-07-22 2001-06-21 Sankyo Company Limited Siklobüten türevleri, bunların hazırlanması ve terapötik kullanımları
GB9919588D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
BR0013593A (pt) 1999-09-01 2002-05-07 Unilever Nv Método para alvejar manchas de tecido
BR0013592A (pt) 1999-09-01 2002-05-07 Unilever Nv Embalagem comercial para alvejar manchas de tecido em um licor de lavagem aquoso, e, uso da mesma
EP1208188A1 (fr) 1999-09-01 2002-05-29 Unilever Plc Composition et procede de blanchiment d'un substrat
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
CA2325358C (fr) 1999-11-10 2005-08-02 Pfizer Products Inc. Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
CN1260227C (zh) 1999-11-10 2006-06-21 武田药品工业株式会社 含氮的五元杂环化合物
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
EP1254114A2 (fr) 2000-01-28 2002-11-06 Melacure Therapeutics AB Nouveaux agonistes et antagonistes de recepteurs des melanocortines
CA2399791A1 (fr) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
JP2004509064A (ja) 2000-04-27 2004-03-25 アボット・ラボラトリーズ 置換フェニルファルネシルトランスフェラーゼ阻害剤
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6417367B1 (en) 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
US20030050211A1 (en) 2000-12-14 2003-03-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Enzymatic detergent compositions
WO2002051396A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
US20040106635A1 (en) 2001-03-29 2004-06-03 Iwao Takamuro Spiroisoquinoline compound, a method for preparing the same and an intermediate thereof
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
MY130373A (en) 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
RU2293083C2 (ru) 2001-11-27 2007-02-10 Ф.Хоффманн-Ля Рош Аг Производные бензотиазола и лекарственное средство на их основе
JP2005510564A (ja) 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
AR037746A1 (es) 2001-12-06 2004-12-01 Novartis Ag Compuestos derivados de amidoacetonitrilo, un procedimiento para su preparacion, un procedimiento para la preparacion de compuestos intermediarios, una composicion para combatir parasitos, un procedimiento para combatir dichos parasitos, y el empleo de dichos derivados para la preparacion de una com
SE0104248D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
CN100383124C (zh) 2002-02-04 2008-04-23 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的喹啉衍生物
IL164212A0 (en) 2002-03-28 2005-12-18 Applied Research Systems Thiazolidine carboxamide derivatives, their preparation and pharmaceutical compositions containing them
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
WO2003091217A1 (fr) 2002-04-26 2003-11-06 Ishihara Sangyo Kaisha, Ltd. Composes pyridine ou sels de ces derniers et herbicides les contenant
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
FR2842805A1 (fr) 2002-07-29 2004-01-30 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide,leur preparation et leur application et therapeutique
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
WO2004029204A2 (fr) 2002-09-27 2004-04-08 Merck & Co., Inc. Pyrimidines substituees
WO2004039795A2 (fr) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Composes amide
EP1560488B1 (fr) 2002-11-05 2010-09-01 Glaxo Group Limited Agents antibacteriens
AU2003290333A1 (en) 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of imidazo(1,5-a)pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
EP1625115A1 (fr) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Derives pyrimidiques substitues
EP1660454A1 (fr) * 2003-07-07 2006-05-31 Vernalis (R&D) Limited Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels
EP1776362A1 (fr) 2003-07-18 2007-04-25 Virochem Pharma Inc. Composes spiro et procedes pour moduler une activite de recepteur de chimiokime
US7094791B2 (en) 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
WO2005021545A1 (fr) 2003-09-03 2005-03-10 Galapagos Nv Derives d'imidazo[1,5-a]pyridine ou d'imidazo[1,5-a]piperidine et leur utilisation dans la preparation d'un medicament dirige contre les troubles lies au recepteur 5-ht2a
GB0320983D0 (en) 2003-09-08 2003-10-08 Biofocus Plc Compound libraries
EP1786816A4 (fr) 2003-09-10 2009-11-04 Virochem Pharma Inc Composes de spirohydantoine et procedes de modulation de l'activite des recepteurs de chimiokine
WO2005046683A1 (fr) * 2003-10-07 2005-05-26 Renovis, Inc. Derives d'amide utilises comme ligands du canal ionique et compositions pharmaceutiques et methodes d'utilisation de ces derives
WO2005042524A1 (fr) 2003-10-30 2005-05-12 Virochem Pharma Inc. Carboxamide de pyridine et methodes permettant d'inhiber l'integrase du vih
CA2555133A1 (fr) 2004-02-04 2005-09-01 Pfizer Products Inc. Composes de quinoline substitues
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
CA2561791A1 (fr) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Composes heterocycliques non-imidazole
DE102004022897A1 (de) 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2005115374A1 (fr) 2004-05-29 2005-12-08 7Tm Pharma A/S Ligands du recepteur crth2 utilises a des fins therapeutiques
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
DE102004031323A1 (de) 2004-06-29 2006-01-19 Bayer Cropscience Ag Substituierte Pyridazincarboxamide und Derivate hiervon
JP2008511552A (ja) * 2004-08-30 2008-04-17 ニューロメッド ファーマシューティカルズ リミテッド カルシウムチャネルブロッカーとしての尿素誘導体
AR050926A1 (es) 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
KR100677149B1 (ko) 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
EP1829863A4 (fr) 2004-11-26 2009-04-22 Takeda Pharmaceutical Derive d'acide arylalcanoique
EP1831194A4 (fr) 2004-12-21 2009-12-02 Astrazeneca Ab ANTAGONISTES HETEROCYCLIQUES DE MCHr1 ET LEURS APPLICATIONS THERAPEUTIQUES
US20080207677A1 (en) 2004-12-31 2008-08-28 Gpc Biotech Ag Napthyridine Compounds As Rock Inhibitors
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1844003A4 (fr) 2005-01-27 2010-09-22 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
WO2006094246A2 (fr) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Modulateurs de sirtuine a base de n-arylmethyl benzamide
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP2008545744A (ja) 2005-06-02 2008-12-18 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト フェニルアルキル置換ヘテロアリール誘導体
ES2536351T3 (es) 2005-06-13 2015-05-22 Merck Sharp & Dohme Limited Agentes terapéuticos
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
CA2609319C (fr) 2005-07-15 2014-02-04 Nissan Chemical Industries, Ltd. Composes thiophenes et activateurs du recepteur thrombopoietine
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
WO2007017093A1 (fr) 2005-08-04 2007-02-15 Bayer Healthcare Ag Derives amides d'acide 2-benzyloxy-benzoique substitue
EP1764098A1 (fr) 2005-09-17 2007-03-21 Speedel Experimenta AG Dérivés de diaminoalcols et leur utilization pour le traitement de la malaria, de la maladie d'Alzheimer et du SIDA
CA2628875A1 (fr) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryle-urees servant a traiter une neuropathie diabetique
US20090176791A1 (en) 2005-11-10 2009-07-09 Bayer Healthcare Ag Diaryl Ureas for Treating Pulmonary Hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
EP1962829A1 (fr) 2005-12-15 2008-09-03 Bayer HealthCare AG Urees de diaryle pour le traitement des infections virales
CA2633411A1 (fr) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryle-urees pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
JP2009524656A (ja) 2006-01-27 2009-07-02 アストラゼネカ・アクチエボラーグ アミド置換キノリン
JP2009527459A (ja) 2006-02-23 2009-07-30 武田薬品工業株式会社 縮合窒素含有複素環化合物
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
EP2010493B1 (fr) 2006-04-12 2016-01-27 Merck Sharp & Dohme Corp. Composés de pyridylamide antagonistes des canaux calciques de type t
JP2009538317A (ja) 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
GB0611152D0 (en) 2006-06-06 2006-07-19 Ucb Sa Therapeutic agents
WO2008003746A1 (fr) 2006-07-06 2008-01-10 Bayer Cropscience Sa Nouveaux dérivés de n-(4-pyridin-2-ylbutyle) carboxamide, procédé de préparation et utilisation comme fongicides
CN101611009A (zh) 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
CA2661459A1 (fr) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Amides di-aromatiques substitues en tant qu'inhibiteurs de la glyt1
US7834023B2 (en) 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008056687A1 (fr) 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
AU2007321920A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
WO2008063670A1 (fr) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs de métalloprotéases hétérobicycliques
EP2121621B1 (fr) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Modulateurs lxr et fxr
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20080293711A1 (en) 2007-03-08 2008-11-27 Clark Michael P Chemokine receptor modulators
EP2146715A4 (fr) 2007-04-11 2011-08-31 Merck Sharp & Dohme Antagonistes du récepteur cgrp comprenant des groupes terminaux amide tertiaire, sulfamide, carbamate et urée
ES2504565T3 (es) 2007-06-05 2014-10-08 Merck Sharp & Dohme Corp. Antagonistas del receptor CGRP de carboxamida heterocíclica
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009023179A2 (fr) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Entités chimiques bicycliques azotées pour traiter les infections virales
EP2188295A4 (fr) 2007-08-10 2011-11-16 Crystalgenomics Inc Dérivés de pyridine et leurs procédés d'utilisation
WO2009038812A1 (fr) 2007-09-20 2009-03-26 Amgen Inc. Dérivés de pipéridine condensée, utiles en tant que ligands des récepteurs vanilloïdes
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
WO2009072621A1 (fr) 2007-12-07 2009-06-11 Nissan Chemical Industries, Ltd. Composé dihydroazole substitué et agent antiparasitaire
WO2009117269A1 (fr) 2008-03-18 2009-09-24 Merck & Co., Inc. 4-hydroxypyrimidine-5-carboxamides substitués
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
AR071310A1 (es) 2008-04-11 2010-06-09 Merck Serono Sa Sulfonamidas
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
CA2727243A1 (fr) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Quinoleines 3- et 6-substituees ramifiees en tant qu'antagonistes de recepteur cgrp
RU2011102471A (ru) 2008-06-25 2012-07-27 Байер Шеринг Фарма Акциенгезелльшафт (De) Диарилмочевины для лечения сердечной недостаточности
ES2610882T3 (es) * 2008-08-19 2017-05-03 Janssen Pharmaceutica, N.V. Antagonistas del receptor al mentol frío
CN101343313B (zh) 2008-09-03 2011-11-16 南京农业大学 一种葡萄糖二肽类化合物及其制备方法和用途
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
UY32525A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
MX2011011428A (es) * 2009-05-01 2011-11-29 Raqualia Pharma Inc Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
CA2761639C (fr) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Derives de carboxamide substitues par aryle comme inhibiteurs des canaux calciques ou sodiques
WO2010141330A1 (fr) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh Dérivés d'amides d'acide 6,7-dihydro-5h-imidazo [1,2-a] imidazole-3-carboxylique
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
CA2769512C (fr) 2009-07-29 2019-07-09 Duke University Compositions renfermant des antagonistes du recepteur fp et leur utilisation pour inhiber la croissance des poils
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
CA2786277A1 (fr) 2010-01-06 2011-07-14 Joseph P. Errico Methodes et compositions pour le developpement de medicaments cibles
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
US20110212969A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
TW201211053A (en) 2010-05-10 2012-03-16 Nissan Chemical Ind Ltd Spiro compound and drug for activating adiponectin receptor
WO2011146300A1 (fr) 2010-05-17 2011-11-24 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de prolylcarboxypeptidase
ES2660611T3 (es) 2010-05-27 2018-03-23 Bayer Cropscience Ag Derivados de ácido piridinilcarboxílico como fungicidas
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
CN103201279A (zh) 2010-11-05 2013-07-10 赛诺米克斯公司 作为trpm8的调节剂有用的化合物
RS63320B1 (sr) 2010-12-08 2022-07-29 The U S A As Represented By The Secretary Department Of Health And Human Services Supstituisani pirazolopirimidini kao aktivatori glukocerebrozidaze
US20140088187A1 (en) 2010-12-14 2014-03-27 Beth Israel Deaconess Medical Center Androgen receptor inhibitors and methods of use thereof
PT2652025T (pt) 2010-12-15 2018-11-02 Ppg Europe B V Composição secante e a sua utilização
US20130324522A1 (en) 2010-12-17 2013-12-05 The Rockefeller University Insect odorant receptor antagonists
WO2012118850A1 (fr) 2011-02-28 2012-09-07 Array Biopharma Inc. Inhibiteurs de sérine/thréonine kinase
WO2012120398A1 (fr) 2011-03-04 2012-09-13 Pfizer Limited Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
WO2012177896A1 (fr) 2011-06-24 2012-12-27 Amgen Inc. Antagonistes de trpm8 et leur utilisation dans le cadre thérapeutique

Also Published As

Publication number Publication date
KR20140045507A (ko) 2014-04-16
AU2012272895B2 (en) 2015-01-22
MX2013015274A (es) 2014-03-31
EP2723717A2 (fr) 2014-04-30
US9096527B2 (en) 2015-08-04
CO6852073A2 (es) 2014-01-30
EA201490152A1 (ru) 2014-05-30
UY34160A (es) 2012-08-31
TW201311643A (zh) 2013-03-16
PE20140868A1 (es) 2014-07-18
MY157429A (en) 2016-06-15
CN103906733A (zh) 2014-07-02
BR112013033316A2 (pt) 2017-01-31
CR20140037A (es) 2014-03-13
AU2012272895A1 (en) 2013-04-11
US20140171639A1 (en) 2014-06-19
CL2013003715A1 (es) 2014-06-27
CA2839699A1 (fr) 2012-12-27
US20130157996A1 (en) 2013-06-20
US8710043B2 (en) 2014-04-29
TN2013000529A1 (en) 2015-03-30
WO2012177893A2 (fr) 2012-12-27
AP2013007331A0 (en) 2013-12-31
JP2014527511A (ja) 2014-10-16
AR086750A1 (es) 2014-01-22
PH12013502611A1 (en) 2014-04-28
TWI448454B (zh) 2014-08-11
US20140171406A1 (en) 2014-06-19
WO2012177893A3 (fr) 2013-06-13
TW201429948A (zh) 2014-08-01

Similar Documents

Publication Publication Date Title
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
EP2827856A4 (fr) Composés et compositions pour le traitement d'affections musculaires
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
EA200901373A1 (ru) Аминогетероциклические соединения
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MA35444B1 (fr) Ligands du récepteur ep1
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators